CA2279349C - Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation - Google Patents

Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation Download PDF

Info

Publication number
CA2279349C
CA2279349C CA002279349A CA2279349A CA2279349C CA 2279349 C CA2279349 C CA 2279349C CA 002279349 A CA002279349 A CA 002279349A CA 2279349 A CA2279349 A CA 2279349A CA 2279349 C CA2279349 C CA 2279349C
Authority
CA
Canada
Prior art keywords
composition
radiolabeled
stabilizer
protein
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002279349A
Other languages
English (en)
Other versions
CA2279349A1 (fr
Inventor
Paul O. Zamora
Michael J. Marek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhomed Inc
Original Assignee
Rhomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhomed Inc filed Critical Rhomed Inc
Publication of CA2279349A1 publication Critical patent/CA2279349A1/fr
Application granted granted Critical
Publication of CA2279349C publication Critical patent/CA2279349C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilisation d'acide ascorbique et de ses dérivés pour stabiliser des protéines et des peptides radiomarqués en évitant la perte du radio marquage par oxydation et l'autoradiolyse. L'acide ascorbique est ajouté après le radiomarquage, avec éventuellement la période d'incubation requise, mais avant l'administration au patient.
CA002279349A 1996-02-02 1997-02-03 Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation Expired - Fee Related CA2279349C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1102796P 1996-02-02 1996-02-02
US60/011,027 1996-02-02
PCT/US1997/001695 WO1997028181A2 (fr) 1996-02-02 1997-02-03 Stabilisation apres marquage de proteines et de peptides radiomarquees

Publications (2)

Publication Number Publication Date
CA2279349A1 CA2279349A1 (fr) 1997-08-07
CA2279349C true CA2279349C (fr) 2007-09-25

Family

ID=21748542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279349A Expired - Fee Related CA2279349C (fr) 1996-02-02 1997-02-03 Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation

Country Status (3)

Country Link
AU (1) AU2526497A (fr)
CA (1) CA2279349C (fr)
WO (1) WO1997028181A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1311301A2 (fr) * 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions
MXPA03007595A (es) * 2001-02-26 2003-12-04 Bristol Myers Squibb Pharma Co Analogos de acido ascorbico para metalorradiofarmaceuticos.
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CA3016901C (fr) * 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Compositions d'immunoglobulines anti-cd45 radio-marquees stabilisees
WO2017200943A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides sélectifs du récepteur du glucagon et méthodes pour les employer
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401646A (en) * 1981-05-08 1983-08-30 University Patents Inc. Method and apparatus for purifying materials radiolabeled with technetium-99m
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
EP0600992B1 (fr) * 1991-08-29 2000-09-20 Mallinckrodt Medical, Inc. Utilisation de l'acide gentisique ou de l'alcool gentisyle pour stabiliser des peptides et proteines radiomarques
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging

Also Published As

Publication number Publication date
CA2279349A1 (fr) 1997-08-07
AU2526497A (en) 1997-08-22
WO1997028181A2 (fr) 1997-08-07
WO1997028181A3 (fr) 1997-10-09

Similar Documents

Publication Publication Date Title
CA2279349C (fr) Composition pharmaceutique stabilisee avec un ascorbate et methode pour son utilisation
US6066309A (en) Post-labeling stabilization of radiolabeled proteins and peptides
AU650629B2 (en) Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5460785A (en) Direct labeling of antibodies and other protein with metal ions
WO1997028181A9 (fr) Stabilisation apres marquage de proteines et de peptides radiomarquees
JP3853354B2 (ja) 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤
EP0804252B1 (fr) Agents chelateurs metalliques renfermant thiol, diamide et monoamine
EP0759786B1 (fr) Conjugues peptide-chelate metallique se liant a la somatostatine
US5277892A (en) In vivo lymphocyte tagging
US6685912B2 (en) Post-labeling stabilization of radiolabeled proteins and peptides
AU8057098A (en) Radioprotectant for peptides labeled with radioisotope
US5130118A (en) Methods and materials for the preparation of metal labelled antibody solutions
KR101055700B1 (ko) 면역세포 영상화 및 탐지를 위한 양기능성킬레이트제와 만노실 인혈청알부민의 결합체 및 그의 방사성동위원소 표지 화합물
Griffiths et al. Technetium‐99m, rhenium‐186, and rhenium‐188 direct‐labeled antibodies
Mardirossian et al. The stability of 99Tcm directly labelled to an Fab'antibody via stannous ion and mercaptoethanol reduction
Saha Characteristics of specific radiopharmaceuticals
Verbeke et al. Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells
US20030165427A1 (en) Tuftsin metallopeptide analogs and uses thereof
US5643549A (en) Leukostimulatory agent for in vivo leukocyte tagging
De Castiglia et al. Optimization of biomolecules labelling with rhenium-188 using direct and indirect methods
AU2694495A (en) Monoamine, diamide, thiol-containing metal chelating agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140204